Journal
PEDIATRIC NEUROLOGY
Volume 128, Issue -, Pages 67-74Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.pediatrneurol.2021.10.004
Keywords
Guideline; Protocol; Antiseizure medication; Neonatal seizures; Levetiracetam; Phenobarbital; Fosphenytoin; Neonatal critical care
Categories
Ask authors/readers for more resources
This study evaluated neonatal seizure management pathways in level IV neonatal intensive care units in the United States, finding areas of consensus such as prompt EEG confirmation of seizures and administration of intravenous benzodiazepines, but also substantial heterogeneity in optimal second-line ASM, dosing, and timing of discontinuation. Further research is needed to address these areas of variability.
Objective: Seizures are a common neonatal neurologic emergency. Many centers have developed pathways to optimize management. We evaluated neonatal seizure management pathways at level IV neonatal intensive care units (NICUs) in the United States to highlight areas of consensus and describe aspects of variability. Methods: We conducted a descriptive analysis of 11 neonatal seizure management pathways from level IV NICUs that specialize in neonatal neurocritical care including guidelines for electroencephalography (EEG) monitoring, antiseizure medication (ASM) choice, timing, and dose. Results: Study center NICUs had a median of 70 beds (interquartile range: 52-96). All sites had 24/7 conventional EEG initiation, monitoring, and review capability. Management pathways uniformly included prompt EEG confirmation of seizures. Most pathways included a provision for intravenous benzodiazepine administration if either EEG or loading of ASM was delayed. Phenobarbital 20 mg/kg IV was the first-line ASM in all pathways. Pathways included either fosphenytoin or levetiracetam as the second-line ASM with variable dosing. Third-line ASMs were most commonly fosphenytoin or levetiracetam, with alternatives including topiramate or lacosamide. All pathways provided escalation to continuous midazolam infusion with variable dosing for seizures refractory to initial medication trials. Three pathways also included lidocaine infusion. Nine pathways discussed ASM discontinuation after resolution of acute symptomatic seizures with variable timing. Conclusions: Despite a paucity of data from controlled trials regarding optimal neonatal seizure management, there are areas of broad agreement among institutional pathways. Areas of substantial heterogeneity that require further research include optimal second-line ASM, dosage, and timing of ASM discontinuation. (c) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available